Financial Performance - The company's operating revenue for Q1 2023 was CNY 361,577,520.44, representing a year-on-year increase of 20.16%[3] - The net profit attributable to shareholders for the same period was CNY 52,097,979.79, reflecting a growth of 34.92% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 47,333,866.04, up by 36.35% year-on-year[3] - Basic earnings per share for Q1 2023 were CNY 0.18, an increase of 38.46% compared to the same period last year[3] - Operating profit for Q1 2023 was ¥72,315,240.14, up 41.4% from ¥51,109,848.62 in Q1 2022[15] - Net profit attributable to shareholders of the parent company was ¥52,097,979.79, representing a 35% increase from ¥38,612,671.22 in Q1 2022[16] - The company reported a total comprehensive income of ¥57,766,277.96 for Q1 2023, compared to ¥41,416,184.78 in Q1 2022[16] Cash Flow - The net cash flow from operating activities reached CNY 67,675,594.49, showing a significant increase of 139.13%[5] - The net cash flow from operating activities for Q1 2023 was ¥67,675,594.49, a significant increase from ¥28,301,006.76 in Q1 2022, representing a growth of approximately 139.5%[19] - Total cash inflow from investment activities was ¥364,144,218.91, compared to ¥205,314,748.68 in the previous year, indicating an increase of about 77.2%[19] - The net cash flow from investment activities was -¥185,035,220.76, an improvement from -¥350,894,954.10 year-over-year[19] - Cash inflow from financing activities totaled ¥90,000,000.00, up from ¥62,680,988.54 in Q1 2022, marking an increase of approximately 43.7%[20] - The net cash flow from financing activities was ¥42,601,794.97, a decrease from ¥57,691,827.75 in the same quarter last year[20] - The company reported a total cash outflow from operating activities of ¥295,927,774.42, slightly lower than ¥299,380,153.10 in the previous year[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,438,122,662.94, up 2.29% from the end of the previous year[3] - The total current assets reached RMB 1,039,380,009.55, compared to RMB 994,114,382.02 in the previous year, indicating an increase of about 4.6%[11] - The total liabilities stood at RMB 1,039,380,009.55, reflecting a rise from RMB 994,114,382.02, which is an increase of about 4.6%[11] - Total liabilities decreased slightly to ¥640,594,851.89 from ¥643,851,468.73 in the previous period[12] - The total non-current assets amounted to RMB 1,398,742,653.39, slightly up from RMB 1,389,498,619.80, indicating a growth of about 0.2%[11] Shareholder Information - The company reported a total of 15,647 common shareholders at the end of the reporting period[6] - The top shareholder, Gao Bo Investment (Hong Kong) Limited, holds 31.37% of the shares, with 26,000,000 shares pledged[7] - The company reported a total of 3,905,332 shares held by major shareholder Zhou Xinwei, with 3,625,592 shares held through a margin account[9] - Total equity attributable to shareholders of the parent company increased to ¥1,775,966,899.04 from ¥1,723,868,919.25[12] Research and Development - Research and development expenses increased to ¥17,971,542.32, up 37.5% from ¥13,117,131.96 in Q1 2022[15] Market Strategy - The company plans to continue expanding its market presence and investing in new product development[15]
维力医疗(603309) - 2023 Q1 - 季度财报